Siglec-5 (CD170) Can Mediate Inhibitory Signaling in the Absence of Immunoreceptor Tyrosine-based Inhibitory Motif Phosphorylation*

Siglec-5 (CD170) is a member of the recently described human CD33-related siglec subgroup of sialic acid binding Ig-like lectins and is expressed on myeloid cells of the hemopoietic system. Similar to other CD33-related siglecs, Siglec-5 contains two tyrosine-based motifs in its cytoplasmic tail implicated in signaling functions. To investigate the role of these motifs in Siglec-5-dependent signaling, we used transfected rat basophil leukemia cells as a model system. Tyrosine phosphorylation of Siglec-5 led to recruitment of the tyrosine phosphatases SHP-1 and SHP-2, as seen in both pull-down assays and microscopy. Siglec-5 could efficiently inhibit FcϵRI-mediated calcium fluxing and serotonin release after co-cross-linking. Surprisingly, a double tyrosine to alanine mutant of Siglec-5 could still mediate strong inhibition of serotonin release in the absence of detectable tyrosine phosphorylation, whereas a double tyrosine to phenylalanine mutant lost all inhibitory activity. In comparison, suppression of Siglec-5-dependent adhesion to red blood cells was reversed by either tyrosine to alanine or tyrosine to phenylalanine mutations of the membrane proximal tyrosine-based motif. Using an in vitro phosphatase assay with synthetic and recombinant forms of the cytoplasmic tail, it was shown that a double alanine mutant of Siglec-5 had weak, but significant SHP-1 activating properties similar to those of wild type, non-phosphorylated cytoplasmic tail, whereas a double phenylalanine mutant was inactive. These findings establish that Siglec-5 can be classified as an inhibitory receptor with the potential to mediate SHP-1 and/or SHP-2-dependent signaling in the absence of tyrosine phosphorylation.

[1]  J. Dayer,et al.  Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3‐kinase‐mediated intracellular signaling , 2005, European journal of immunology.

[2]  F. Lopez,et al.  The Membrane-Proximal Immunoreceptor Tyrosine-Based Inhibitory Motif Is Critical for the Inhibitory Signaling Mediated by Siglecs-7 and -9, CD33-Related Siglecs Expressed on Human Monocytes and NK Cells1 , 2004, The Journal of Immunology.

[3]  James C Paulson,et al.  Negative Regulation of T Cell Receptor Signaling by Siglec-7 (p70/AIRM) and Siglec-9* , 2004, Journal of Biological Chemistry.

[4]  Ajit Varki,et al.  Large-scale sequencing of the CD33-related Siglec gene cluster in five mammalian species reveals rapid evolution by multiple mechanisms. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Jinhua Lu,et al.  Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells. , 2004, Immunobiology.

[6]  P. Crocker,et al.  The murine inhibitory receptor mSiglec‐E is expressed broadly on cells of the innate immune system whereas mSiglec‐F is restricted to eosinophils , 2004, European journal of immunology.

[7]  A. Rosenthal,et al.  Systematic identification of immunoreceptor tyrosine-based inhibitory motifs in the human proteome. , 2004, Cellular signalling.

[8]  P. Virgo,et al.  Identification of the CD33‐related Siglec receptor, Siglec‐5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias , 2003, British journal of haematology.

[9]  P. Crocker,et al.  Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake , 2003, Molecular Microbiology.

[10]  Eric O Long,et al.  Vav1 Dephosphorylation by the Tyrosine Phosphatase SHP-1 as a Mechanism for Inhibition of Cellular Cytotoxicity , 2003, Molecular and Cellular Biology.

[11]  Stephen D Holmes,et al.  Characterization of Siglec-5 (CD170) expression and functional activity of anti-Siglec-5 antibodies on human phagocytes. , 2003, Experimental hematology.

[12]  D. Jackson The unfolding tale of PECAM‐1 , 2003, FEBS letters.

[13]  Z. Zhao,et al.  Crystal Structure of Human Protein-tyrosine Phosphatase SHP-1* , 2003, The Journal of Biological Chemistry.

[14]  S. Watt,et al.  Human Siglec‐5: tissue distribution, novel isoforms and domain specificities for sialic acid‐dependent ligand interactions , 2002, British journal of haematology.

[15]  P. Crocker,et al.  Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling. , 2002, Current opinion in structural biology.

[16]  M. López-Botet,et al.  Cloning of two new splice variants of Siglec-10 and mapping of the interaction between Siglec-10 and SHP-1. , 2002, Biochemical and biophysical research communications.

[17]  A. Varki,et al.  Cloning and Characterization of Human Siglec-11 , 2002, The Journal of Biological Chemistry.

[18]  Tracey L. Catina,et al.  SHP-1- and Phosphotyrosine-Independent Inhibitory Signaling by a Killer Cell Ig-Like Receptor Cytoplasmic Domain in Human NK Cells1 , 2002, The Journal of Immunology.

[19]  C. Anderson,et al.  Regulated Expression and Inhibitory Function of FcγRIIb in Human Monocytic Cells* , 2002, The Journal of Biological Chemistry.

[20]  Zhenbao Yu,et al.  Identification and Characterization of S2V, a Novel Putative Siglec That Contains Two V Set Ig-like Domains and Recruits Protein-tyrosine Phosphatases SHPs* , 2001, The Journal of Biological Chemistry.

[21]  A. Varki,et al.  Siglecs, sialic acids and innate immunity. , 2001, Trends in immunology.

[22]  K. Nichols,et al.  CD150 Association with Either the SH2-Containing Inositol Phosphatase or the SH2-Containing Protein Tyrosine Phosphatase Is Regulated by the Adaptor Protein SH2D1A1 , 2001, The Journal of Immunology.

[23]  M. Thomas,et al.  Molecular Cloning of MIS, a Myeloid Inhibitory Siglec, That Binds Protein-tyrosine Phosphatases SHP-1 and SHP-2* , 2001, The Journal of Biological Chemistry.

[24]  D. Banville,et al.  mSiglec-E, a novel mouse CD33-related siglec (sialic acid-binding immunoglobulin-like lectin) that recruits Src homology 2 (SH2)-domain-containing protein tyrosine phosphatases SHP-1 and SHP-2. , 2001, The Biochemical journal.

[25]  G. Feng,et al.  The protein tyrosine phosphatase Shp-2 regulates RhoA activity , 2000, Current Biology.

[26]  L. Lanier,et al.  Immune inhibitory receptors. , 2000, Science.

[27]  D. Pei,et al.  Determination of the binding specificity of the SH2 domains of protein tyrosine phosphatase SHP-1 through the screening of a combinatorial phosphotyrosyl peptide library. , 2000, Biochemistry.

[28]  P. Crocker,et al.  Siglec-9, a Novel Sialic Acid Binding Member of the Immunoglobulin Superfamily Expressed Broadly on Human Blood Leukocytes* , 2000, The Journal of Biological Chemistry.

[29]  D. McVicar,et al.  Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. , 2000, Blood.

[30]  M. Colonna,et al.  Human inhibitory and activating Ig-like receptors which modulate the function of myeloid cells. , 2000, Microbes and infection.

[31]  T. Woodford-Thomas,et al.  The sialoadhesin CD33 is a myeloid‐specific inhibitory receptor , 1999, European journal of immunology.

[32]  R. Biassoni,et al.  Identification and Molecular Cloning of P75/Airm1, a Novel Member of the Sialoadhesin Family That Functions as an Inhibitory Receptor in Human Natural Killer Cells , 1999, The Journal of experimental medicine.

[33]  C. Buckley,et al.  The Myeloid-specific Sialic Acid-binding Receptor, CD33, Associates with the Protein-tyrosine Phosphatases, SHP-1 and SHP-2* , 1999, The Journal of Biological Chemistry.

[34]  M. Augustus,et al.  Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33. , 1998, Blood.

[35]  S. Shoelson,et al.  Crystal Structure of the Tyrosine Phosphatase SHP-2 , 1998, Cell.

[36]  L Meyaard,et al.  LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. , 1997, Immunity.

[37]  A. Trautmann,et al.  Reconstituted Killer Cell Inhibitory Receptors for Major Histocompatibility Complex Class I Molecules Control Mast Cell Activation Induced via Immunoreceptor Tyrosine-based Activation Motifs* , 1997, The Journal of Biological Chemistry.

[38]  A. Saltiel,et al.  Expression of catalytically inactive Syp phosphatase in 3T3 cells blocks stimulation of mitogen-activated protein kinase by insulin. , 1994, The Journal of biological chemistry.

[39]  J. Kuriyan,et al.  Crystal structures of peptide complexes of the amino-terminal SH2 domain of the Syp tyrosine phosphatase. , 1994, Structure.

[40]  N. Tonks,et al.  Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes. , 1991, Science.

[41]  C. Nathan,et al.  Putting the brakes on innate immunity: a regulatory role for CD200? , 2001, Nature Immunology.